Ten days after Cochrane published its review of anti-amyloid monoclonal antibodies for early Alzheimer's disease, Medicare coverage still runs through the same registry machinery. Cochrane found that the drugs probably make little to no difference to memory and thinking decline at 18 months and that successful amyloid removal does not seem associated with clinically meaningful effects.[1] The paper's Apr 21 account of four institutions silent while Medicare kept paying named silence as the policy problem. The Apr 24 Day Nine brief said the omission had hardened. Day Ten makes it durable.

The clinical finding is not subtle. Cochrane reviewed 17 studies involving 20,342 people and concluded that anti-amyloid monoclonal antibodies have trivial cognitive effect at 18 months while increasing amyloid-related imaging abnormalities, including brain swelling and microbleeds.[1] For every 1,000 people using monoclonal antibodies, 119 developed brain swelling versus 12 per 1,000 on placebo.[1]

CMS still lists its coverage with evidence development pathway. Patients with mild cognitive impairment or mild dementia due to Alzheimer's disease may receive FDA-approved monoclonal antibodies through approved studies and registries, with baseline and six-month data submissions through a dedicated portal.[2] The registry is not an abstraction. It is the pipe through which payment and evidence collection continue.

There are defensible reasons for regulators not to overreact to a review within ten days. Agencies must verify methods, consult clinicians, and evaluate whether registry evidence answers different questions than trial meta-analysis. But a public acknowledgment is not an overreaction. It is the minimum courtesy owed to patients and clinicians when a high-ranking evidence body says the benefit is trivial.

Eisai's rebuttal arrived quickly. Regulators' response did not. That asymmetry is why the story belongs in the paper. Industry can defend a product in hours. Government can continue paying for it in silence.

The bedside consequence is easy to miss because the policy language is sterile. A family deciding whether to start a loved one on an infusion therapy is not choosing between a Cochrane abstract and a CMS web page. It is choosing amid hope, fear, MRI scheduling, amyloid confirmation, infusion logistics, and safety monitoring. If the agency has read the review and believes the existing pathway still serves patients, it should say so. If it is reviewing the evidence, it should say that. If it has done neither, that is the most troubling answer.

MSM tends to make this a debate over the amyloid hypothesis. X tends to make it a scandal of reimbursement. The paper's frame is narrower and harsher: an evidence shock has entered a payment system built to collect evidence, and the system has not publicly acknowledged the shock.

Day Ten is not a magic threshold. It is a round number with institutional meaning. Two news cycles, two trading weeks, and one weekend later, the infusion chair remains scheduled. Silence is not neutral when it pays the bill.

-- NORA WHITFIELD, Chicago